Angle-supported phakic IOLs banned in France

Article

Angle-supported phakic IOLs can no longer be sold or implanted in France because of their association with significant endothelial cell loss, which was discovered in patients two to three years after implantation.

Angle-supported phakic IOLs can no longer be sold or implanted in France because of their association with significant endothelial cell loss, which was discovered in patients two to three years after implantation.

Manufacturers, IOLTech/Carl Zeiss Meditec and Corneal have withdrawn the Vivarte and NewLife phakic IOLs and the Icare lens, respectively, in accordance with the French Agency for Sanitary Safety of Health Products (AFSSAPS) orders.

A retrospective study was organized to determine the incidence and cause and it was found that, out of 2,324 lenses implanted, 27 had to be removed because of significantly high cell loss.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
© 2025 MJH Life Sciences

All rights reserved.